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Abstract
Several risk factors like obesity and hyperlipidemia were described for endometrial cancer. Here, the nuclear NAD-dependent 
histone-deacetylase Sirtuin1 (SIRT1) seems to be important. SIRT1 is also involved in cell regulatory mechanisms and can 
serve as tumor promotor or suppressor. Its role in tumor biology is not clear yet. In this study, we evaluated and correlated 
the SIRT1 expression with patients’ tumor characteristics in endometrioid and clear-cell cancer of the uterus. 65 paraffin-
embedded samples of patients with endometrial and clear-cell cancer of the uterus were immunohistochemically stained and 
SIRT1 expression was evaluated by immunoreactive score. The results were correlated to clinical and pathological tumor 
characteristics as well as to the expression of ARID1A and β-Catenin. The staining was significantly more intensive in 
uterine endometrioid carcinoma compared to uterine clear-cell carcinoma (p = 0.007). The expression of SIRT1 correlated 
significantly with the membranous expression of β-Catenin (p = 0.028) and ARID1A (p = 0.021). Patients with positive Sir-
tuin1 expression had a significantly better progression-free survival (p = 0.042), the overall survival showed a trend towards 
a better prognosis (p = 0.070). SIRT1 expression seems to be associated with improved progression-free survival in uterine 
cancer (endometrioid and clear-cell) and is correlated to the tumor suppressors β-Catenin and ARID1A. Further studies are 
necessary to elucidate the role of SIRT1 in uterine and ovarian cancer and its potential as a therapeutic target.
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Introduction
Endometrial cancer is the most common gynecologic cancer 
in developed countries (Siegel et al. 2018). The incidence in 
Germany is 11,700 (new diseases per year), which makes it 
the fourth common cancer among women in Germany [Rob-
ert Koch-Institut (Hrsg.) (2010)]. Traditionally, subtypes are 
divided into class I– estrogen dependent (low grade endome-
trioid cancers) and class II (estrogen-independent high-grade 
serous or clear-cell carcinomas) (Kurman RJ 2014). Several 
risk factors like obesity, hyperlipidemia, infertility or late 
onset of the menopause were described (Ali 2014; Bokhman 
1983). Another risk factor seems to be the history of endo-
metriosis (Zucchetto et al. 2009). Different mutations, like 
ARID1A and β-Catenin are common in endometriosis and 
associated cancers, where they can act as tumor suppressors 
(Wiegand et al. 2010).
Current cancer research focuses on epigenetic altera-
tions. These can be caused by histone deacetylases (HDAC), 
for example Sirtuins 1–7. Sirtuin1 (SIRT1) belongs to the 
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NAD + -dependent class III HDAC and is located in the 
nucleus (Banks et al. 2008; Michishita et al. 2005). Like 
other molecules being responsible for epigenetic altera-
tions, SIRT1 affects the cell-cycle via multiple pathways 
(Pinzone et al. 2013): besides the regulation of lipid and 
glucose metabolism (Brunet et al. 2004), it is also involved 
in the pathogenesis of cancer by deacetylation of different 
histones (Vaquero et al. 2004). SIRT1 downregulates the 
tumor suppressor p53 and Fox P3 by deacetylation (Chadha 
et al. 2019) and interaction with other proteins are described 
(Pinzone et al. 2013; Vaziri et al. 2001). By multiple interac-
tions, SIRT1 can act either as tumor promotor or as tumor 
suppressor (Lin and Fang 2013). Nevertheless, experiments 
have shown that mice with overexpression of SIRT1 have 
lower cancer risk and less metabolic dysfunction (Herranz 
et al. 2010).
In endometrial cancer, its expression is described to be 
generally increased (Asaka et al. 2015; Bartosch et al. 2016) 
as well as in endothelial ovarian cancers (Jang et al. 2009). 
In ovarian cancer, SIRT1 overexpression was correlated with 
improved overall survival (Jang et al. 2009). In endometrial 
cancer, its role regarding tumor growth is not clear yet (De 
et al. 2018). Some studies showed an increased cisplatin 
resistance with lower survival rates (Asaka et al. 2015), 
while other studies described an inhibition of cancer pro-
gression by stimulation of SIRT1 (Deus et al. 2017).
This study aimed to determine the expression of SIRT1 in 
endometrioid and clear-cell carcinomas of the uterus and to 




65 patients with endometrial or clear-cell cancer of the 
uterus, who had undergone surgery at the Department of 
Gynecology at Ludwig–Maximilians-University in Munich 
between 1990 and 2001, were included in this study. Inclu-
sion criteria were surgery in our department due to endome-
trioid or clear cell cancer of the uterus and samples being 
available as well as histo-pathological data. Due to the low 
number, other subtypes were excluded. Besides these crite-
ria, no pre-selection was performed. The distribution was as 
follows: 59 patients with endometrioid uterine carcinoma 
and six with clear cell uterine carcinoma. Clinical, patho-
logical and survival data were provided by the tumor registry 
of Munich. Patients’ characteristics are shown in Table 1.
Ethics approval
All samples were originally collected during surgery proce-
dure for histopathological diagnostics and no longer used for 
it. Patient data were completely anonymized. Authors were 
blinded for clinical information during the analyses. The 
study was performed conforming the Declaration of Helsinki 
and was approved by the local ethics committee of the LMU 
Munich (reference number 19-249).
Immunohistochemistry
Tissue microarray paraffin blocks were cut at 2–3 µm and 
prepared by heat-treatment. This was followed by the 
Table 1  Patients characteristics
SD standard deviation
n %
Age (average ± SD) 64.6 (± 10.4)
Histopathology
 Endometrioid uterine carcinoma 59 90.8
 Clear cell uterine carcinoma 6 9.2
Grading
 Grade 1 18 27.7
 Grade 2 24 36.9


















 At least one 11 16.9
 Not available 3 4.6
Survival (over 177 months)
 Right censured 32 49.2
 Died 32 49.2
 Not available 1 1.5
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assessment of the primary antibody with an incubation 
time of 60 min at room temperature (Anti-SIRT1-Anti-
body; polyclonal antibody; dilution 1:180; company: Atlas 
antibodies; order number: HPA006295; antibody valida-
tion by isotype control and system control). After detec-
tion of the primary antibody, chromogen was put on sam-
ples and a counter staining with hematoxylin took place. 
All samples were stained at the Department of Pathology, 
Ludwig–Maximilians-University, Munich.
The expression was finally analyzed by the Remmele 
immunoreactive score (IRS) in a blind process. The intensity 
of the staining was scored between 0 and 3 (0 = no intensity, 
1 = low intensity, 2 = moderate intensity, 3 = high intensity) and 
multiplied with a score representing the percentage of stained 
cells (0 = 0%; 1 = 1–10%; 2 = 11–50%; 3 = 51–80%; 4 > 80%). 
SIRT1 was dichotomized into no expression and expression. 
In previous studies, the same collective was already stained 
immunohistochemically with antibodies against ARID1A 
(ARID1A/BAF250a Rabbit mAb; New England Biolabs 
GmbH; antibody validation by manufacturer) and β-Catenin 
(β-Catenin Mouse IgG-1; Roche, Ventana, ready to use; anti-
body validation by manufacturer) (Wu and Roberts 2013). All 
those staining’s were performed at the Department of Pathol-
ogy, Ludwig-Maximilians-University, Munich. To control the 
staining of SIRT1, non-pathological samples of human tonsils 
were stained.
For analyzing the images the light microscope “Immu-
nohistochemistry Type 307–148.001 512 686” by Leitz was 
used. The camera was produced by Fissler (IH-Camera 3CCD 
Colour Video Camera). For image acquisition, the software 
“Discuss Version 4,602,017-#233 (Carl C. Hilgers Technical 
Office) was used. Image bit depth: 24 mm; time and space 
resolution data: 760 + 574 pixel.
Statistics
IBM SPSS Statistics version 23 (Armonk, NY, USA) was 
used for statistical analyses. To calculate bivariate correla-
tions, Spearman’s-rank-correlation coefficient was employed. 
To compare independent groups, we used non-parametric tests 
(NPAR: Kruskal–Wallis test, Mann–Whitney U test). Survival 
times were shown by Kaplan–Meier estimates and calculated 
by log-rank-test. For improved clarity, these results are shown 
in years, while calculations were performed in months. For 
statistical significance p value had to be < 0.05.
Results
Expression of SIRT1
Non-pathological tissue microarrays (TMA) of tonsils sam-
ples were used to control the staining.
Regarding the whole sample, eight TMAs were not 
evaluable (12.3%) due to insufficient tissue quality. In our 
study group, SIRT1 was expressed in 35.4% of all samples 
with a median IRS score of 4 (SD: ± 2.89; Fig. 1). 16.9% 
of the evaluated samples did not show any expression at 
all.
The expression of SIRT1 was significantly higher in 
endometrioid carcinoma (median: 4; SD ± 2.66) compared 
to clear cell carcinoma (median: 0; SD ± 2.01; p = 0.007; 
Fig. 2; Table 2).
Fig. 1  Sirtuin1 expression in endometrioid uterine carcinoma with an 
IRS score of 4: examples for Sirtuin1 positives cells are marked by 
→. Scale bar 200 µm, small pictures 100 µm
Fig. 2  SIRT1 expression in clear-cell uterine (n = 6) and endometri-
oid uterine (n = 59) cancer shown in a boxplot. There is a significant 
higher IRS of the Sirt1 expression in endometrioid uterine cancer 
(IRS = 4) compared to clear-cell uterine cancer (IRS = 0); p = 0.007
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Correlation to pathological characteristics
No significant difference was detected regarding T-stage, 
FIGO-stage, grading and lymph-node status (pN) (Table 2). 
This was also the case when histological subtypes were ana-
lyzed. SIRT1 did not correlate to specific risk factors for 
endometrial carcinoma suh as diabetes (p = 0.858), obesity 
(p = 0.983) or hypertension (p = 0.539; Table 2).
Correlation to survival
Patients with SIRT1 expression in endometrioid cancer 
of the uterus to show better overall-survival than patients 
without SIRT1 expression (p = 0.070; Fig. 3a; Table 2). 
Progression-free survival was significantly better in uterine 
endometrioid and clear-cell cancer for patients with SIRT1 
expression (p = 0.042; Fig. 3b; Table 2).
Correlation to other expression markers
The expression of SIRT1 in uterine and ovarian endometri-
oid and clear-cell carcinomas correlated significantly with 
a high expression of β-Catenin in the membrane (p = 0.028; 
ρ = 0.333, p = 0.011; Table  3). Additionally, the SIRT1 
expression was positively correlated with high ARID1A 
expression but the correlation coefficient ρ was not signifi-
cant (p = 0.021; ρ = 0.026, p = 0.850; Table 3).
Table 2  Results of correlation between clinical pathologic character-
istics including survival and expression of Sirtuin1
OS overall survival, PFS progression-free survival, KW Kruskal–
Wallis test
Significant results and important differences are shown in bold
Uterine cancer (n = 65)
Median (± SD) p
Histology 0.007
 Endometrioid 4 (± 2.66)
 Clear-cell 0 (± 2.01)
T-stage (Gr.) 0.267
 T1 4 (± 2.46)
 T2 4 (± 3.37)
 T3 6 (± 3.70)
 T4
pN 0.572
 pN0 4 (± 2.25)
 pN1 4 (± 2.64)
FIGO 0.161
 I 4 (± 1.94)
 II 4 (± 2.23) 
 III 6 (± 3.44)
 IV 4 (± 2.58)
Grading 0.760
 G1 4 (± 2.72)
 G2 4 (± 3.01)






Fig. 3  Survival in regard to SIRT1 expression [a trend to better 
overall survival in uterine cancer in case of SIRT1 expression (red) 
compared to missing SIRT1 expression (black) (p = 0.070); b sig-
nificant better progression-free survival in uterine cancer in case of 
SIRT1 expression in uterine cancer (red) compared to missing SIRT1 
expression (black) (p = 0.042)]
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Discussion
Endometrial cancer is classified into type-I (containing 
endometrioid types) and type-II cancers (including clear-cell 
carcinomas) (Kurman RJ 2014). Many studies exist observ-
ing the prognostic value of different epigenetic changes in 
uterine cancers, but less is known about the role of SIRT1 
in these cancer types. The aim of the study was to evaluate 
the prognostic value of SIRT1 expression in endometrioid 
and clear-cell cancer of the uterus.
This histone-deacetylase is known to be involved in the 
pathophysiology of metabolic diseases and neurodegenera-
tive disorders (Lavu et al. 2008). Regarding cancer progres-
sion its role is controversially discussed and is known to 
differ in respect to tissue and cancer entity: SIRT1 expres-
sion does not seem to have any prognostic significance in 
retinoblastoma (Batra et al. 2015). In contrast, in adenocarci-
noma and small cell carcinoma of the lung, SIRT1 seems to 
be associated with poor survival, which can also be observed 
in large B-cell lymphoma and in clear cell renal cell carci-
nomas (Chen et al. 2017; Jang et al. 2008; Noh Baek et al. 
2013a, b; Noh Kang et al. 2013a, b; Wang and Wang 2016).
In tumor cells of renal clear cell carcinoma SIRT1 was 
described to be associated with poor survival and was sug-
gested to be a tumor promotor (Noh Kang et al. 2013a, b). 
We could not confirm that these finding can be generalized: 
SIRT1 expression in uterine clear-cell-carcinomas was not 
associated with poor survival rates in our study, but the num-
ber of clear-cell carcinomas was limited. This supports the 
assumption that the role of SIRT1 has to be examined spe-
cifically for each cancer entity and subtype.
Regarding gynecologic cancer entities, the role of SIRT1 
is studied in cervical cancer. Here its knockdown seems to 
inhibit progression of paclitaxel-resistant cells (Xia and 
Zhou 2018) and its expression seems to predict the efficacy 
of neoadjuvant chemotherapy (Teramae et al. 2015). Until 
now, there are only few studies focusing on SIRT1 as prog-
nostic factor in endometrial and clear cell carcinomas of 
the uterus. Up to now, the SIRT1 expression has only been 
described to be generally increased in endometrial can-
cer (Asaka et al. 2015; Bartosch et al. 2016) as well as in 
endothelial ovarian cancer types (Jang et al. 2009). In some 
studies, an increased cisplatin resistance with lower survival 
rates was observed (Asaka et al. 2015), while other studies 
showed that cancer progression was inhibited by stimula-
tion of SIRT1 (Deus et al. 2017). Our results show that an 
increased SIRT1 expression in uterine cancer types (endo-
metrioid and clear-cell) is correlated to a longer progression-
free survival which supports the thesis that SIRT1 acts as 
a tumor suppressor. Studies already highlighted the role of 
the SIRT1-p53 pathway in this context (Gomes et al. 2016).
Also in regard to other gynecologic tumors, such as ovar-
ian cancer, the role of SIRT1 expression is inconsistent: 
regarding the most common ovarian cancer types (serous, 
mucinous, endometrioid, clear-cell), an increased SIRT1 
expression is significantly correlated to shorter survival 
rates (Mvunta et al. 2017). In contrast, Jang et al. showed in 
serous carcinomas that a decreased expression is correlated 
with decreased survival rates and high FIGO stages (Jang 
et al. 2009).
Heckel et al. found that the expression of ARID1A and 
absent nuclear β-Catenin staining were positive prognostica-
tors in endometrioid and clear-cell carcinoma of the uterus 
and the ovaries (Heckl et al. 2018). We detected a positive 
correlation of SIRT1 expression in the examined entities 
with both proteins, ARID1A and β-Catenin. SIRT1 being 
a histon-deacetylase, one could hypothesize that its over-
expression could lead to an activation of the transcription 
of the other proteins named above. The protein ARID1A is 
part of the SWI/SNF chromatin remodeling complex and is 
supposed to be a tumor suppressor (Wu and Roberts 2013). 
Expression of ARID1A as well as expression of SIRT1 cor-
related to better survival rates. Regarding β-Catenin, another 
tumor suppressor and part of the Wnt-pathway (Heckl et al. 
2018), positive membranous and negative nuclear staining 
correlated to better survival rates, as well as SIRT1 expres-
sion. Both correlations support our thesis that SIRT1 func-
tions as tumor suppressor in the examined uterine cancer 
types.
As in other histone deacetylases already tested, SIRT1 
can be a target for individual therapy. Reservatol, a natural 
phenol, is known to stimulate SIRT1 (Deus et al. 2017). By 
this stimulation, an inhibition of cancer progression can be 
induced in vitro (breast cancer cells) (Deus et al. 2017). This 
approach could also be reasonable in uterine cancer.
A limitation of this analysis was the low number of speci-
men, especially of clear-cell carcinomas (6). Due to this fact, 
our findings can be seen as hypothesis and further studies 
with higher sample numbers would be useful and could 
probably help to confirm our thesis.
In conclusion, we detected a correlation of SIRT1 
expression and β-Catenin and ARID1A in endometrioid 
and clear-cell cancer types of the uterus. Furthermore, pro-
gression-free survival was better in patients with SIRT1 
overexpressing uterine tumors, while only a trend was 
observed in regard to overall survival. To our knowledge, 
this is the first analysis showing a correlation of SIRT1 
Table 3  Correlation between SIRT1 and β-Catenin and ARID1A
SIRT1
p (NPAR) Correlation coefficient ρ
ARID1A 0.021 0.026 (p = 0.850)
β-Catenin (membra-
nous)
0.028 0.333 (p = 0.011)
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and survival in uterine cancer. These results suggest that 
SIRT1 may act as tumor suppressor in this examined can-
cer entity. Further studies are necessary to elucidate the 
actual role of SIRT1 in endometrial cancer and its correla-
tion with ARID1A an β-Catenin. SIRT1 may act as poten-
tial target in a tailored therapy approach. In this context, 
the potential of Reservatol should be further analyzed.
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